NCT04229979Phase 3Active not recruiting

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Study sponsor: Sellas Life Sciences Group

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-12Estimated

Enrollment · participants127Actual

Source updated2025-10-01Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-10-01 · 2 fields changed

Actual enrollment decreased by 1 participants

− Before

~~128 participants (actual)~~

+ After

127 participants (actual)

Primary completion date changed

− Before

~~Sep 2025~~

+ After

Dec 2025

Check registry source